Why the IMNN-001 and PARP inhibitor pairing could matter more than the standalone data in ovarian cancer
FDA engagement signals cautious progress for AEON Biopharma Inc. in complex biologics space (NYSE American: AEON)
Read More 5 minute read Pharma Industry News FDA engagement signals cautious progress for AEON Biopharma Inc. in complex biologics space (NYSE American: AEON) AEON Biopharma advances ABP-450 biosimilar strategy. Discover what this means for BOTOX competition, pricing, and biotech market dynamics. bySoujanya RaviMarch 28, 2026